LXR-623 is a full agonist of LXR-β that can penetrate the blood–brain barrier and has been shown to have anti-GBM cell effects by promoting ABCA1/G1-mediated cholesterol efflux while reducing LDLR-mediated cholesterol uptake6. Here, NR1H2 is linked to glioblastoma.